<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052688</url>
  </required_header>
  <id_info>
    <org_study_id>SQNM T21-305</org_study_id>
    <nct_id>NCT01052688</nct_id>
  </id_info>
  <brief_title>Noninvasive Screening for Affected Pregnancies: Assay Development &amp; Optimization in Affected Pregnancies</brief_title>
  <acronym>CHARMM-AP</acronym>
  <official_title>Noninvasive Screening for Fetal Chromosomal Aneuploidy and Abnormality: Assay Development &amp; Optimization in Affected Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequenom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequenom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect samples for the purpose of developing and optimizing an in vitro noninvasive&#xD;
      prenatal diagnostic (NIPD) test. The NIPD test employs circulating cell free (ccff) DNA&#xD;
      extracted from whole blood samples collected from women who are pregnant with a fetus&#xD;
      previously determined to have a chromosomal abnormality. The NIPD result will be compared to&#xD;
      the standard test results obtained from other test methods such as karyotype, FISH, QF-PCR,&#xD;
      and/or any commercially available NIPD test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NIPD result compared to standard test results</measure>
    <time_frame>baseline</time_frame>
    <description>Result of NIPD test will be compared to the standard test results obtained by karyotype, FISH, QF-PCR, and/or commerical NIPD result.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Aneuploidy</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <description>Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maternal blood draw of 30 to 50ml</intervention_name>
    <description>Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.</description>
    <arm_group_label>Pregnant Women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, white blood cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who have been definitively diagnosed by amniocentesis, CVS or QF/PCR as&#xD;
        carrying a fetus with aneuploidy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is female&#xD;
&#xD;
          -  Subject is 18 years or older&#xD;
&#xD;
          -  Subject is no less than 8 and no more than 36 weeks gestation&#xD;
&#xD;
          -  Subject provides a signed and dated informed consent&#xD;
&#xD;
          -  Subject agrees to provide one or more 30-50mL blood sample(s) in accordance with the&#xD;
             protocol&#xD;
&#xD;
          -  Subject has a current pregnancy in which the fetus is known to have chromosomal&#xD;
             aneuploidy (e.g. T13, T18, T21)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-singleton pregnancy in which only one fetus is known to have a chromosomal&#xD;
             aneuploidy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan-Sebastian Saldivar, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sequenom, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Perinatal Care Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Grossmount</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IGO</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Perinatal Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Healthcare at Frost Street</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reiter, Hill, Johnson and Nevin</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fetal Diagnostic Institute of the Pacific</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02902-2499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Down syndrome, aneuploidy, amniocentesis, chorionic villus sampling, Trisomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Samples and data are used in research and development of a noninvasive prenatal test. However, sample data used in publications will be shared as per requirements of the journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

